

# **BioPhausia**

## **PRESS RELEASE**

### **The BioPhausia Board proposes the Annual General Meeting to authorize the Board to decide on a new share issue**

The Board of Directors of BioPhausia AB (publ) proposes to the Annual General Meeting on April 26 1999 to authorize the Board to decide on a new issue of Series A and/or Series B shares, whereby the issue may be effected without regard to shareholders' preferential rights. The shares thus issued may result in a total increase in share capital of not more than SEK 25,000,000 (10,000,000 shares at a par value of SEK 2.50 each).

Johannes Norrby, Chairman of the Board of Directors, issued the following statement: "BioPhausia needs a capital contribution, approximately 50 MSEK, primarily in order to promote the projects within tumour and trauma treatment areas, secondly to bridge the time until RescueFlow® and Krillase® will generate royalty and similar license revenues. The proposal to authorize the Board to decide on a share issue will increase the number of alternatives for the Board."

Uppsala, April 6, 1999

*Based on its contact network and know-how, primarily in connective tissue biology, **BioPhausia** is developing products for licensing to well-established pharmaceutical companies with strong marketing organizations.*

*The product and project portfolio includes **RescueFlow®**, a resuscitation solution, **Krillase®** for the debridement of chronic wounds (clinical phase III), and preclinical projects in the **tumor** and **trauma** treatment areas.*

For additional information, please call:

Johannes Norrby, Chairman of the Board, phone: +46 (0)70-606 24 97

BioPhausia AB (publ)  
AR 4, S-741 74 Uppsala, Sweden  
Phone: +46 18 34 99 00  
Fax: +46 18 34 94 95  
E-mail: [info@biophausia.se](mailto:info@biophausia.se)  
Org.nr. 556485-0153

BioPhausia AB (publ)  
AR 4, S-741 74 Uppsala, Sweden  
Phone: +46 18 34 99 00  
Fax: +46 18 34 94 95  
E-mail: [info@biophausia.se](mailto:info@biophausia.se)  
Org.nr. 556485-0153